PureFacts Financial Solutions acquires Quartal Financial Solutions to become a global WealthTech leader
17.11.2020 21:41:00 EET | Business Wire | Press release
PureFacts Financial Solutions, a leading WealthTech provider of fees, reporting and AI-powered predictive analytics solutions, has acquired Quartal Financial Solutions, Europe’s leading provider of fee billing and commission solutions for the financial and insurance industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117006164/en/
PureFacts Financial Solutions acquires Quartal Financial Solutions (Graphic: Business Wire)
This acquisition further strengthens PureFacts’ ability to provide mission critical, AI-driven and regulatory compliant fee solutions to its marquee clients. Additionally, the combined organization expands the company’s global reach to bring market-leading solutions and opportunities to all its stakeholders.
These two successful companies both have industry-leading expertise in calculating fees and commissions. Together, they will provide the most powerful fee platform in the global financial marketplace. The combined entity will benefit from strengthening their core capabilities in data aggregation, machine learning and financial industry expertise.
This is the second successful acquisition completed by PureFacts this year, coming on the heels of its acquisition of CRM consulting firm, VennScience in May 2020. Led by Gerard Daniels, PureFacts Head of Corporate Development and supported by world class advisors including PricewaterhouseCoopers Corporate Finance Inc. and Goodmans LLP, the team continues to identify strategic acquisitions that best serve its clients and accelerate PureFacts’ strategy.
PureFacts global head office will remain in Toronto, Canada while the European head office will be located at Quartal’s office in Zurich, Switzerland. PureFacts CEO Robert Madej will take the helm of the new corporate entity, with PureFacts President Rajini McRae expanding her role to include the global businesses. Quartal CEO Thierry Zuppinger has been appointed as the General Manager Europe and Asia for the combined entity.
“With any acquisition or partnership that we undertake, we always ensure our values are aligned and our clients’ interests are at the centre,” says Robert Madej, PureFacts CEO. “In this case, we are further excited by the Quartal team’s enthusiasm and the willingness of the key executive team to become shareholders in PureFacts.”
“We are thrilled about the combination of our businesses and are looking forward to working with Rob and his team, who have proven to be a perfect fit as a strategic partner to Quartal’s business going forward,” says Thierry Zuppinger, CEO of Quartal Financial Solutions. “Joining forces with PureFacts will significantly accelerate our joint journey to becoming a truly global market and mindshare leader in the fee and commission management domain; allowing us to better service our clients globally.”
Quartal Financial Solutions is a market-leading provider of fee and commission management, and revenue and expense lifecycle management software for the financial and insurance industries. The company was founded in 1999 and currently has more than 30 clients with over 50 software installations in 15 countries across Europe, United States, Middle East, Africa, and the Asia-Pacific region. Their clients enjoy reduced operating costs, higher performances, quick Return on Investment, and reduced technology obsolescence through the use of their technologically advanced solutions. www.quartalfs.com
Ranked a WealthTech100 Company and Top 12 Canadian Innovator, PureFacts Financial Solutions provides wealth management solutions for the financial services industry in Canada, the USA, and Europe. PureFacts’ mission is to create meaningful wealth solutions that help people live their best lives. They provide their clients with transformational WealthTech solutions to future-proof their business and accelerate growth by leveraging their expertise in wealth management data aggregation, complex calculations, Artificial Intelligence and machine learning. www.purefacts.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117006164/en/
Contact information
Mr. Gerard Daniels
Head of Corporate Development, PureFacts
gerard.daniels@purefacts.com
Mr. Thierry Zuppinger
CEO, Quartal Financial Solutions
thierry.zuppinger@quartalfs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom